KPMG in India announces appointment of Dr. Ajaz Hussain as Senior Advisor, Risk Consulting
New Delhi [India], Mar 8 (ANI): KPMG in India has announced the appointment of Dr. Ajaz Hussain as Senior Advisor to the firm from 1 January 2017.
Changing regulations, adoption of new technologies and increasing demands across geographies around compliance have compelled KPMG in India to bring forth a proactive and continuous quality compliance programme which aims to deliver effective results. In this endeavor, Dr. Ajaz Hussain will serve as a Senior Advisor to KPMG in India.
Dr. Ajaz Hussain brings a wealth of international pharmaceutical regulatory and business experience to KPMG in India, including his decade-long tenure with the United States Food and Drug Administration (US FDA), Center for Drug Evaluation and Research (CDER).
He has led some of the US Food and Drug Administration's major initiatives to develop regulatory policies that already have and are likely to continue to have a significant impact on product development and approval in many geographies.
He has been honored by US FDA on multiple occasions for his contribution and insights.
Dr. Ajaz Hussain is currently serving as the President of The National Institute for Pharmaceutical Technology and Education, a not-for-profit educational organization which is a collaboration of 17 major universities in the U.S. Grants from US FDA primarily fund the research programmes at the institute. He also serves as an advisory to multiple pharmaceutical companies around the globe and also supports several regulatory agencies by conducting training programmes.
Dr. Ajaz has over 80 publications to his credit. He is a Fellow of the American Association of Pharmaceutical Scientists and the Swiss Society of Pharmaceutical Sciences. Dr. Ajaz has also worked with Sandoz AG and Philip Morris International in the U.S., and Wockhardt Limited in India.
Dr. Ajaz's deep association with the Indian pharmaceutical industry over the years and his exposure to the compliance challenges and issues faced led to KPMG in India to bringing him onboard as a Senior Advisor.
He would be guiding the KPMG risk consulting practice as an industry and regulatory specialist while defining a compliance roadmap for KPMG clients. KPMG in India is currently associated with multiple organisations, institutes and government bodies in the sector and expanding its services in regulatory and quality compliance to pharmaceutical, medical device, R&D and CRAMS companies.
On his appointment, Dr. Ajaz said, "I am excited and looking forward to working with KPMG in India to build dynamic progressive service offerings for the pharmaceutical sector that will reduce regulatory uncertainty and business complexity to create a competitive advantage for KPMG's clients."
On Dr. Ajaz's appointment, Utkarsh Palnitkar, Partner and National Head – Infrastructure, Government and Healthcare and National Head- Life Sciences, KPMG in India, said: "KPMG in India has a strong, customer-centric, sector-focused approach towards the life sciences sector. We have continually, based on customer feedback, expanded our service offerings and endeavour to constantly add to our team of expert and experienced professionals. In continuation of this tradition and as part of our commitment to our clients, we welcome Dr. Ajaz on board, a renowned and vastly experienced US FDA professional" (ANI)